U. Abshagen, S. Sporl-radun, and J. Marinow, Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers, Eur J Clin Pharmacol, vol.17, pp.305-308, 1980.

B. S. Andresen, S. Olpin, and B. J. Poorthuis, Clear correlation of genotype with disease phenotype in verylong-chain acyl-CoA dehydrogenase deficiency, Am J Hum Genet, vol.64, pp.479-494, 1999.

C. Angelini, A. Federico, and H. Reichmann, Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders, Eur J Neurol, vol.13, pp.923-929, 2006.

T. Aoyama, J. M. Peters, and N. Iritani, Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha), J Biol Chem, vol.273, pp.5678-5684, 1998.

G. D. Barish, V. A. Narkar, and R. M. Evans, PPAR delta: a dagger in the heart of the metabolic syndrome, J Clin Invest, vol.116, pp.590-597, 2006.

J. Berger and D. E. Moller, The mechanisms of action of PPARs, Annu Rev Med, vol.53, pp.409-435, 2002.

J. P. Bonnefont, F. Demaugre, and C. Prip-buus, Carnitine palmitoyltransferase deficiencies, Mol Genet Metab, vol.68, pp.424-440, 1999.

J. P. Bonnefont, F. Djouadi, and C. Prip-buus, Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects, Mol Aspects Med, vol.25, pp.495-520, 2004.

R. Cadorniga, R. Herrero, and P. Pastoriza, Comparative pharmacokinetics of two oral bezafibrate preparations, Eur J Drug Metab Pharmacokinet Spec, vol.3, pp.261-267, 1991.

Z. Cai, A. Taddei, and D. N. Sheppard, Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl j channel, J Biol Chem, vol.281, pp.1970-1977, 2006.

T. K. Chaudhuri and S. Paul, Protein-misfolding diseases and chaperone-based therapeutic approaches, Febs J, vol.273, pp.1331-1349, 2006.

M. Deschauer, T. Wieser, and S. Zierz, Muscle carnitine palmitoyltransferase II deficiency: clinical and molecular genetic features and diagnostic aspects, Arch Neurol, vol.62, pp.37-41, 2005.

F. Djouadi, C. J. Weinheimer, and J. E. Saffitz, A genderrelated defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice, J Clin Invest, vol.102, pp.1083-1091, 1998.

F. Djouadi, J. P. Bonnefont, and L. Thuillier, Correction of fatty acid oxidation in Carnitine Palmitoyl Transferase IIdeficient cultured skin fibroblasts by bezafibrate, Pediatr Res, vol.54, pp.446-451, 2003.

F. Djouadi, F. Aubey, D. Schlemmer, and J. Bastin, Peroxisome proliferator activated receptor d (PPARd) agonist but not PPARa corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells, J Clin Endocrinol Metab, vol.90, pp.1791-1797, 2005.

F. Djouadi, F. Aubey, and D. Schlemmer, Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders, Hum Mol Genet, vol.14, pp.2695-2703, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-02896287

J. N. Feige, L. Gelman, and L. Michalik, From molecular action to physiological outputs: Peroxisome proliferatoractivated receptors are nuclear receptors at the crossroads of key cellular functions, Prog Lipid Res, vol.45, pp.120-159, 2006.

J. Gloerich, L. Ijlst, and R. J. Wanders, Bezafibrate induces FALDH in human fibroblasts; implications for Sjogren-Larsson syndrome, Mol Genet Metab, vol.89, pp.111-115, 2006.

S. Gobin-limballe, F. Djouadi, and F. Aubey, Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy, Am J Hum Genet, vol.81, pp.1133-1143, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-02896262

N. Gregersen, B. S. Andresen, and M. J. Corydon, Mutation analysis in mitochondrial fatty acid oxidation defects: exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship, Hum Mutat, vol.18, pp.169-189, 2001.

T. Gulick, S. Cresci, and T. Caira, The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression, Proc Natl Acad Sci U S A, vol.91, pp.11012-11016, 1994.

M. Haim, M. Benderly, and V. Boyko, Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy, Coron Artery Dis, vol.17, pp.455-461, 2006.

P. J. Isackson, M. J. Bennett, and G. D. Vladutiu, Identification of 16 new disease-causing mutations in the CPT2 gene resulting in carnitine palmitoyltransferase II deficiency, Mol Genet Metab, vol.89, pp.323-331, 2006.

I. Issemann and S. Green, Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators, Nature, vol.347, pp.645-650, 1990.

C. H. Lee, P. Olson, and R. M. Evans, Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors, Endocrinology, vol.144, pp.2201-2207, 2003.

S. S. Lee, T. Pineau, and J. Drago, Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators, Mol Cell Biol, vol.15, pp.3012-3022, 1995.
URL : https://hal.archives-ouvertes.fr/hal-02712129

S. Luquet, J. Lopez-soriano, and D. Holst, Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability, Faseb J, vol.17, pp.2299-2301, 2003.

S. Mandard, M. Muller, and S. Kersten, Peroxisome proliferator-activated receptor alpha target genes, Cell Mol Life Sci, vol.61, pp.393-416, 2004.

T. Meade, R. Zuhrie, and C. Cook, Bezafibrate in men with lower extremity arterial disease: randomised controlled trial, Bmj, vol.325, p.1139, 2002.

J. P. Monk and P. A. Todd, Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia, Drugs, vol.33, pp.539-576, 1987.

S. E. Olpin, Fatty acid oxidation defects as a cause of neuromyopathic disease in infants and adults, Clin Lab, vol.51, pp.289-306, 2005.

R. K. Olsen, B. S. Andresen, and E. Christensen, Clear relationship between ETF/ETFDH genotype and phenotype in patients with multiple acyl-CoA dehydrogenation deficiency, Hum Mutat, vol.22, pp.12-23, 2003.

G. Parenti, A. Zuppaldi, G. Pittis, and M. , Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease, Mol Ther, vol.15, pp.508-514, 2007.

E. R. Pearson, I. Flechtner, and P. R. Njolstad, Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations, N Engl J Med, vol.355, pp.467-477, 2006.

J. M. Peters, T. Aoyama, and A. M. Burns, Bezafibrate is a dual ligand for PPARa and PPARb: studies using null mice, Biochim Biophys Acta, vol.1632, pp.80-89, 2003.

P. Rinaldo, D. Matern, and M. J. Bennett, Fatty acid oxidation disorders, Annu Rev Physiol, vol.64, pp.477-502, 2002.

C. R. Roe, L. Sweetman, and D. S. Roe, Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride, J Clin Invest, vol.110, pp.259-269, 2002.

J. M. Saudubray, D. Martin, and P. De-lonlay, Recognition and management of fatty acid oxidation defects: a series of 107 patients, J Inherit Metab Dis, vol.22, pp.488-502, 1999.

P. S. Shekhawat, D. Matern, and A. W. Strauss, Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: impact of expanded newborn screening on their diagnosis and management, Pediatr Res, vol.57, pp.78-86, 2005.

K. G. Sim, J. Hammond, and B. Wilcken, Strategies for the diagnosis of mitochondrial fatty acid beta-oxidation disorders, Clin Chim Acta, vol.323, pp.37-58, 2002.

J. O. Solis and R. H. Singh, Management of fatty acid oxidation disorders: a survey of current treatment strategies, J Am Diet Assoc, vol.102, pp.1800-1803, 2002.

A. Tenenbaum, M. Motro, and E. Z. Fisman, Dual and panperoxisome proliferator-activated receptors (PPAR) coagonism: the bezafibrate lessons, Cardiovasc Diabetol, vol.4, p.14, 2005.

L. Thuillier, H. Rostane, and V. Droin, Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 deficiency, Hum Mutat, vol.5, pp.493-501, 2003.

J. Vockley and D. A. Whiteman, Defects of mitochondrial betaoxidation: a growing group of disorders, Neuromuscul Disord, vol.12, pp.235-246, 2002.

J. Vockley, R. H. Singh, and D. A. Whiteman, Diagnosis and management of defects of mitochondrial beta-oxidation, Curr Opin Clin Nutr Metab Care, vol.5, pp.601-609, 2002.

Y. X. Wang, C. L. Zhang, and R. T. Yu, Regulation of muscle fiber type and running endurance by PPARdelta, PLoS Biol, vol.2, p.294, 2004.

B. Wilcken, Recent advances in newborn screening, J Inherit Metab Dis, vol.30, pp.129-133, 2007.

B. Wilcken, V. Wiley, and J. Hammond, Screening newborns for inborn errors of metabolism by tandem mass spectrometry, N Engl J Med, vol.348, pp.2304-2312, 2003.